Abbott Laboratories' revenue and return on invested capital could be more consistent. Read why potential investors will need ...
Abbott Laboratories (NYSE:ABT) is largely controlled by institutional shareholders who own 78% of the company Institutions' substantial holdings in Abbott Laboratories implies that they have ...
On Thursday, Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $117.26 which represents a slight increase of $1.33 or 1.15% from the prior close of $115.93. The stock opened at ...
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...
A review application filed by Abbott Healthcare, alleging that the National Pharmaceutical Pricing Authority (NPPA) used ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...
Analysts see big upside for these undervalued health care stocks.
At close: 22 November at 6:16 pm GMT+1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback